Haruhide Kimura
Haruhide Kimura has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Motohisa Suzuki
Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
11 shared publicationsAtsushi Suzuki
Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan
9 shared publicationsKazunori Suzuki
Takeda Pharmaceutical Company Limited, Fujisawa, Japan
9 shared publicationsAkina Harada
Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
8 shared publicationsAkiyoshi Kunugi
Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
7 shared publicationsRyuji Yamada
Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
7 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (6) , 168
Liquid Chromatography/tandem Mass Spectrometry-based Target Engagement of Lysine-specific Demethylase 1 Inhibitor TAK-418 Through Detecting Covalent Adducts in the Brain
Translating pharmacokinetics (PK) and pharmacodynamics (PD) from preclinical to clinical is important in successful development of drugs for central nervou
- 12 October 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (6) , 168
Open AccessLiquid Chromatography/tandem Mass Spectrometry-based Target Engagement of Lysine-specific Demethylase 1 Inhibitor TAK-418 Through Detecting Covalent Adducts in the Brain
Translating pharmacokinetics (PK) and pharmacodynamics (PD) from preclinical to clinical is important in successful development of drugs for central nervou
- Open Access
- 7 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Mitigation of cardiovascular adverse effects while preserving wake-promoting efficacy of orexin receptor 2 − selective agonists
Orexin receptor 2 (OX2R)-selective agonists have potent wake-promoting effects and could be a promising treatment for sleep/wake disorders, such as narcolepsy type 1. However, OX2R agonists may cause cardiovascular (CV) adverse events. In this study, we explored strategies to minimize CV side effects while preserving the wake-promoting efficacy of OX2R-selective agonists, OX-202 and OX-203, in rats. CV parameter analyses using a telemetry system in unrestrained rats revealed that both OX-202 and OX-203 induced elevated blood pressure, which correlated with their central exposure levels. Moreover, in electrophysiological analyses in rat brain slices, OX-202 activated neurons in the rostral ventrolateral medulla, a key brain area regulating CV function, suggesting that CV effects of OX2R agonists may be centrally mediated. A steep increase in plasma OX-202 levels induced immediate wakefulness but elevated blood pressure. A gradual rise in OX-202 plasma levels resulted in delayed wakefulness without blood pressure elevation. Non-awakening and low-level preexposure for 1 h, followed by a steep increase in OX-202 plasma levels, achieved prompt wakefulness without blood pressure elevation. These results highlight that the pharmacokinetic profile is a critical factor for OX2R agonists in achieving potent and prompt wakefulness with a lower risk of blood pressure increase.
- 7 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessMitigation of cardiovascular adverse effects while preserving wake-promoting efficacy of orexin receptor 2 − selective agonists
Orexin receptor 2 (OX2R)-selective agonists have potent wake-promoting effects and could be a promising treatment for sleep/wake disorders, such as narcolepsy type 1. However, OX2R agonists may cause cardiovascular (CV) adverse events. In this study, we explored strategies to minimize CV side effects while preserving the wake-promoting efficacy of OX2R-selective agonists, OX-202 and OX-203, in rats. CV parameter analyses using a telemetry system in unrestrained rats revealed that both OX-202 and OX-203 induced elevated blood pressure, which correlated with their central exposure levels. Moreover, in electrophysiological analyses in rat brain slices, OX-202 activated neurons in the rostral ventrolateral medulla, a key brain area regulating CV function, suggesting that CV effects of OX2R agonists may be centrally mediated. A steep increase in plasma OX-202 levels induced immediate wakefulness but elevated blood pressure. A gradual rise in OX-202 plasma levels resulted in delayed wakefulness without blood pressure elevation. Non-awakening and low-level preexposure for 1 h, followed by a steep increase in OX-202 plasma levels, achieved prompt wakefulness without blood pressure elevation. These results highlight that the pharmacokinetic profile is a critical factor for OX2R agonists in achieving potent and prompt wakefulness with a lower risk of blood pressure increase.
- Open Access
- 17 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16
Effects of an orexin receptor 2-selective agonist on salivary secretion in rats
Narcolepsy type 1 (NT1) is caused by a significant loss of orexin-producing neurons. In clinical trials, multiple orexin receptor 2 (OX2R)-selective agonists (e.g., danavorexton, TAK-994, and oveporexton) improved wakefulness and decreased cataplexy in individuals with NT1. However, OX2R-selective agonists were also reported to induce hypersalivation as an adverse event in a small number of healthy volunteers and in individuals with NT1. Importantly, no objective data supporting these observations are available, and multiple factors can indirectly affect saliva secretion. In this study, we assessed the effect of an OX2R-selective agonist, OX-202, on salivary secretion in anesthetized or freely moving rats using a muscarinic acetylcholine receptor agonist, pilocarpine, as a positive control. Subcutaneous administration of pilocarpine at 1 mg/kg significantly increased the amount of saliva in the oral cavity in both anesthetized and freely moving rats. In contrast, intraperitoneal administration of OX-202 at 100 mg/kg under anesthetized conditions did not increase salivary secretion in rats. Moreover, oral administration of OX-202 (30 and 100 mg/kg) at zeitgeber time 6 (sleep phase) or zeitgeber time 15 (active phase) did not increase salivary secretion in the oral cavity in freely moving rats. In conclusion, OX2R-selective agonists may not directly induce salivary secretion in rats.
- 17 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16
Open AccessEffects of an orexin receptor 2-selective agonist on salivary secretion in rats
Narcolepsy type 1 (NT1) is caused by a significant loss of orexin-producing neurons. In clinical trials, multiple orexin receptor 2 (OX2R)-selective agonists (e.g., danavorexton, TAK-994, and oveporexton) improved wakefulness and decreased cataplexy in individuals with NT1. However, OX2R-selective agonists were also reported to induce hypersalivation as an adverse event in a small number of healthy volunteers and in individuals with NT1. Importantly, no objective data supporting these observations are available, and multiple factors can indirectly affect saliva secretion. In this study, we assessed the effect of an OX2R-selective agonist, OX-202, on salivary secretion in anesthetized or freely moving rats using a muscarinic acetylcholine receptor agonist, pilocarpine, as a positive control. Subcutaneous administration of pilocarpine at 1 mg/kg significantly increased the amount of saliva in the oral cavity in both anesthetized and freely moving rats. In contrast, intraperitoneal administration of OX-202 at 100 mg/kg under anesthetized conditions did not increase salivary secretion in rats. Moreover, oral administration of OX-202 (30 and 100 mg/kg) at zeitgeber time 6 (sleep phase) or zeitgeber time 15 (active phase) did not increase salivary secretion in the oral cavity in freely moving rats. In conclusion, OX2R-selective agonists may not directly induce salivary secretion in rats.
- 31 August 2025
- Published by Springer Nature
- p. 2717-2738
Narcolepsy and Orexin Receptor 2
- Open Access
- 26 March 2025
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 46 (4) , 298-302
M1 receptor positive allosteric modulators discovery approaches
- 26 March 2025
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 46 (4) , 298-302
Open AccessM1 receptor positive allosteric modulators discovery approaches
- 30 October 2024
- Published by Elsevier
- Vol. 102, 267-300
Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism
- 30 October 2024
- Published by Elsevier
- Vol. 102, 267-300
Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism
- Open Access
- 6 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models
Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy. Current medications indicated for NT1 often show limited efficacy, not addressing the full spectrum of symptoms, demonstrating a need for novel drugs. We discovered a parenteral orexin receptor 2 (OX2R) agonist, danavorexton, and an orally available OX2R agonist, TAK-994; both improving NT1 phenotypes in mouse models and individuals with NT1. However, danavorexton has limited oral availability and TAK-994 has a risk of off-target liver toxicity. To avoid off-target-based adverse events, a highly potent molecule with low effective dose is preferred. Here, we show that a novel OX2R-selective agonist, TAK-861 [N-{(2S,3R)-4,4-Difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3′,5′-trifluoro[1,1′-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide], activates OX2R with a half-maximal effective concentration of 2.5 nM and promotes wakefulness at 1 mg/kg in mice and monkeys, suggesting ~ tenfold higher potency and lower effective dosage than TAK-994. Similar to TAK-994, TAK-861 substantially ameliorates wakefulness fragmentation and cataplexy-like episodes in orexin/ataxin-3 and orexin-tTA;TetO DTA mice (NT1 mouse models). Compared with modafinil, TAK-861 induces highly correlated brain-wide neuronal activation in orexin-tTA;TetO DTA mice, suggesting efficient wake-promoting effects. Thus, TAK-861 has potential as an effective treatment for individuals with hypersomnia disorders including narcolepsy, potentially with a favorable safety profile.
- 6 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
Open AccessTAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models
Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy. Current medications indicated for NT1 often show limited efficacy, not addressing the full spectrum of symptoms, demonstrating a need for novel drugs. We discovered a parenteral orexin receptor 2 (OX2R) agonist, danavorexton, and an orally available OX2R agonist, TAK-994; both improving NT1 phenotypes in mouse models and individuals with NT1. However, danavorexton has limited oral availability and TAK-994 has a risk of off-target liver toxicity. To avoid off-target-based adverse events, a highly potent molecule with low effective dose is preferred. Here, we show that a novel OX2R-selective agonist, TAK-861 [N-{(2S,3R)-4,4-Difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3′,5′-trifluoro[1,1′-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide], activates OX2R with a half-maximal effective concentration of 2.5 nM and promotes wakefulness at 1 mg/kg in mice and monkeys, suggesting ~ tenfold higher potency and lower effective dosage than TAK-994. Similar to TAK-994, TAK-861 substantially ameliorates wakefulness fragmentation and cataplexy-like episodes in orexin/ataxin-3 and orexin-tTA;TetO DTA mice (NT1 mouse models). Compared with modafinil, TAK-861 induces highly correlated brain-wide neuronal activation in orexin-tTA;TetO DTA mice, suggesting efficient wake-promoting effects. Thus, TAK-861 has potential as an effective treatment for individuals with hypersomnia disorders including narcolepsy, potentially with a favorable safety profile.
- Open Access
- 10 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
Effects of an OX2R agonist on migration and removal of tau from mouse brain
Pathological proteins including tau are produced in neurons and released into interstitial fluid (ISF) in a neural activity-dependent manner during wakefulness. Pathological proteins in ISF can be removed from the brain via the glymphatic pathway during nighttime. Thus, in individuals with Alzheimer’s disease (AD) that have dysregulated sleep/wake rhythm, application of orexin receptor 2 (OX2R) agonists during daytime could recover the efflux of pathological proteins to ISF and indirectly promote the glymphatic pathway by improving the quality of nighttime sleep after proper daytime arousal, resulting in increased removal of these proteins from the brain. We investigated this hypothesis using OX-201, a novel OX2R-selective agonist with a 50% effective concentration of 8.0 nM. Diurnal rhythm of tau release into hippocampal ISF correlated well with neuronal activity and wakefulness in wild-type mice. In both wild-type and human P301S tau transgenic mice, OX-201 induced wakefulness and promoted tau release into hippocampal ISF. Human P301S tau transgenic mice, tested under our conditions, showed longer wakefulness time, which differs from individuals with AD. OX-201 treatment over 2 months did not alter hippocampal tau levels. Although further studies are required, at a minimum OX2R agonists may not exacerbate tau accumulation in individuals with tauopathy, including AD.
- 10 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
Open AccessEffects of an OX2R agonist on migration and removal of tau from mouse brain
Pathological proteins including tau are produced in neurons and released into interstitial fluid (ISF) in a neural activity-dependent manner during wakefulness. Pathological proteins in ISF can be removed from the brain via the glymphatic pathway during nighttime. Thus, in individuals with Alzheimer’s disease (AD) that have dysregulated sleep/wake rhythm, application of orexin receptor 2 (OX2R) agonists during daytime could recover the efflux of pathological proteins to ISF and indirectly promote the glymphatic pathway by improving the quality of nighttime sleep after proper daytime arousal, resulting in increased removal of these proteins from the brain. We investigated this hypothesis using OX-201, a novel OX2R-selective agonist with a 50% effective concentration of 8.0 nM. Diurnal rhythm of tau release into hippocampal ISF correlated well with neuronal activity and wakefulness in wild-type mice. In both wild-type and human P301S tau transgenic mice, OX-201 induced wakefulness and promoted tau release into hippocampal ISF. Human P301S tau transgenic mice, tested under our conditions, showed longer wakefulness time, which differs from individuals with AD. OX-201 treatment over 2 months did not alter hippocampal tau levels. Although further studies are required, at a minimum OX2R agonists may not exacerbate tau accumulation in individuals with tauopathy, including AD.
- Open Access
- 25 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0306099
Orexin receptor 2 agonist activates diaphragm and genioglossus muscle through stimulating inspiratory neurons in the pre-Bötzinger complex, and phrenic and hypoglossal motoneurons in rodents
Orexin-mediated stimulation of orexin receptors 1/2 (OX[1/2]R) may stimulate the diaphragm and genioglossus muscle via activation of inspiratory neurons in the pre-Bötzinger complex, which are critical for the generation of inspiratory rhythm, and phrenic and hypoglossal motoneurons. Herein, we assessed the effects of OX2R-selective agonists TAK-925 (danavorexton) and OX-201 on respiratory function. In in vitro electrophysiologic analyses using rat medullary slices, danavorexton and OX-201 showed tendency and significant effect, respectively, in increasing the frequency of inspiratory synaptic currents of inspiratory neurons in the pre-Bötzinger complex. In rat medullary slices, both danavorexton and OX-201 significantly increased the frequency of inspiratory synaptic currents of hypoglossal motoneurons. Danavorexton and OX-201 also showed significant effect and tendency, respectively, in increasing the frequency of burst activity recorded from the cervical (C3–C5) ventral root, which contains axons of phrenic motoneurons, in in vitro electrophysiologic analyses from rat isolated brainstem–spinal cord preparations. Electromyogram recordings revealed that intravenous administration of OX-201 increased burst frequency of the diaphragm and burst amplitude of the genioglossus muscle in isoflurane- and urethane-anesthetized rats, respectively. In whole-body plethysmography analyses, oral administration of OX-201 increased respiratory activity in free-moving mice. Overall, these results suggest that OX2R-selective agonists enhance respiratory function via activation of the diaphragm and genioglossus muscle through stimulation of inspiratory neurons in the pre-Bötzinger complex, and phrenic and hypoglossal motoneurons. OX2R-selective agonists could be promising drugs for various conditions with respiratory dysfunction.
- 25 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0306099
Open AccessOrexin receptor 2 agonist activates diaphragm and genioglossus muscle through stimulating inspiratory neurons in the pre-Bötzinger complex, and phrenic and hypoglossal motoneurons in rodents
Orexin-mediated stimulation of orexin receptors 1/2 (OX[1/2]R) may stimulate the diaphragm and genioglossus muscle via activation of inspiratory neurons in the pre-Bötzinger complex, which are critical for the generation of inspiratory rhythm, and phrenic and hypoglossal motoneurons. Herein, we assessed the effects of OX2R-selective agonists TAK-925 (danavorexton) and OX-201 on respiratory function. In in vitro electrophysiologic analyses using rat medullary slices, danavorexton and OX-201 showed tendency and significant effect, respectively, in increasing the frequency of inspiratory synaptic currents of inspiratory neurons in the pre-Bötzinger complex. In rat medullary slices, both danavorexton and OX-201 significantly increased the frequency of inspiratory synaptic currents of hypoglossal motoneurons. Danavorexton and OX-201 also showed significant effect and tendency, respectively, in increasing the frequency of burst activity recorded from the cervical (C3–C5) ventral root, which contains axons of phrenic motoneurons, in in vitro electrophysiologic analyses from rat isolated brainstem–spinal cord preparations. Electromyogram recordings revealed that intravenous administration of OX-201 increased burst frequency of the diaphragm and burst amplitude of the genioglossus muscle in isoflurane- and urethane-anesthetized rats, respectively. In whole-body plethysmography analyses, oral administration of OX-201 increased respiratory activity in free-moving mice. Overall, these results suggest that OX2R-selective agonists enhance respiratory function via activation of the diaphragm and genioglossus muscle through stimulation of inspiratory neurons in the pre-Bötzinger complex, and phrenic and hypoglossal motoneurons. OX2R-selective agonists could be promising drugs for various conditions with respiratory dysfunction.
- Open Access
- 1 February 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 132 (3) , 541-552
Effects of the orexin receptor 2 agonist danavorexton on emergence from general anaesthesia and opioid-induced sedation, respiratory depression, and analgesia in rats and monkeys
- 1 February 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 132 (3) , 541-552
Open AccessEffects of the orexin receptor 2 agonist danavorexton on emergence from general anaesthesia and opioid-induced sedation, respiratory depression, and analgesia in rats and monkeys